| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2016: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2014: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
Therapeutic method for in vivo stem cell or gene delivery has not been established on bone engineering though its potential usefulness has been suggested. As experiments, firstly, direct implantation of freshly isolated adipose cells (ADC) with low-dose rhBMP2 to the mouse cranium were performed to assess the potential usefulness of non-cultured (NC) ADC for bone engineering. Then, we have made a try at developing an atelocollagen-based GAM containing naked-plasmid (p) DNAs encoding Runx2 or miR20a. As results, when NC-ADCs were transplanted to mice, remarkable augmented bone-area were observed at 2 weeks of transplantation. Then, when GAMs were manufactured by mixing pDNAs with atelocollagen and β-TCP granules, the newly formed bones surrounded by Osteocalcin-stained area were clearly observed in GAMs containing pRunx2 or pmiR20a on the mouse cranium. We are currently carrying out the additional experiments for clarifying the usefulness of GAM combined with NC-ADCs.
|
